Cellivery Attends JP Morgan Healthcare Conference... "Continuous Meetings Regarding L/O Underway"

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 2nd that it will participate in the JP Morgan Healthcare Conference held in San Francisco, USA, from the 12th to the 15th, upon invitation from global pharmaceutical companies.

Cellivery will hold consecutive meetings for license-out (L/O) negotiations regarding its major pipelines and proprietary platform technology, the pharmacological substance in vivo delivery technology TSDT.

A Cellivery representative stated, “The new drug for treating ataxia (recombinant protein), which is being co-developed with Takeda, is in the final milestone 3 stage," adding, "Takeda invited us to this JPM event to discuss the L/O contract.” The representative further said, “We also want to have meetings regarding the non-exclusive L/O of the TSDT platform technology and the Parkinson’s disease treatment candidate iCP-Parkin, which is expected to be due to the very positive evaluation of the TSDT platform technology within Takeda.”

Takeda Pharmaceutical conducts research and development mainly at the Shonan Research Center and its headquarters in Japan. Business development is primarily carried out by Takeda USA based in Boston, making it a multinational pharmaceutical company with a unique structure. The company explained that the meeting counterpart from Takeda will be the business development (BD) team of Takeda USA.

In addition to Takeda, the company explained that more than 10 global pharmaceutical companies have requested participation in the 2020 JP Morgan Healthcare Conference, including Qilu, a Chinese pharmaceutical company currently negotiating L/O for the pancreatic cancer anticancer drug iCP-SOCS3; a Nordic-based pharmaceutical company requesting licensing for the Parkinson’s disease treatment candidate iCP-Parkin; and a Western European-based pharmaceutical company wishing to sign a master collaboration agreement (MCA) for the TSDT platform technology.

Cellivery plans to hold consecutive meetings with global pharmaceutical companies interested in the L/O of major pipelines such as the Parkinson’s disease treatment candidate and pancreatic cancer anticancer drug, as well as the non-exclusive L/O of the TSDT platform technology, which enables cell-to-cell transfer. One-on-one meetings with more than 10 big pharma companies have already been confirmed. Additionally, they are coordinating further meetings with more than 15 other global pharmaceutical companies, emphasizing that forming partnerships with new global pharmaceutical companies will be the main content and goal of the meetings.

Now in its 38th year, the JP Morgan Healthcare Conference is the world’s largest event in the new drug development field, connecting pharmaceutical and biotech companies with promising new drug pipelines to investors. The 2020 JPM event is expected to host over 400 companies and more than 8,000 corporate representatives. A company representative emphasized, “Takeda, with whom we currently have contracts and collaborations, and a global top 3 pharmaceutical company first met and discussed collaboration and contracts at the JPM Healthcare Conference,” adding, “As this event is held every early year, it will be a meaningful occasion to gauge global trends and the future of Cellivery.”

This content was produced with the assistance of AI translation services.